Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02915224
- Locations
- 🇬🇷
Attiko Hospital; Haematology Clinic, Athens, Greece
🇬🇷General Hospital G. Papanikolaou; Hematology, BMT Unit, Thessaloniki, Greece
🇬🇷AXEPA Pathology Section; A Pathology Clinic, Thessaloniki, Greece
A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT02913443
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇨🇦The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada
🇪🇸Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain
Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT02913482
- Locations
- 🇺🇸
Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois, United States
🇵🇱Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology, Gda?sk, Poland
🇺🇦Ams of Ukraine; Inst. of Neurology, Psychiatry & Narcology, Kharkov, Ukraine
A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)
- Conditions
- Breast Cancer
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 629
- Registration Number
- NCT02913456
- Locations
- 🇧🇬
MHAT Nadezhda, Sofia, Bulgaria
🇦🇹Klinikum Klagenfurt; Abt. f. Hämatologie u. internistische Onkologie, Klagenfurt, Austria
🇧🇬Mdozs - Russe, Ruse, Bulgaria
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 231
- Registration Number
- NCT02908685
- Locations
- 🇯🇵
Minami Kyushu National Hospital, Kagoshima, Japan
🇯🇵Miyagi Children's Hospital, Miyagi, Japan
🇯🇵Shiga Medical Center for Children, Shiga, Japan
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 514
- Registration Number
- NCT02908672
- Locations
- 🇺🇸
St. Luke's University Health network, Bethlehem, Pennsylvania, United States
🇫🇷Institut Gustave Roussy; Dermatologie, Villejuif, France
🇩🇪Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, Germany
A Non-Interventional Safety Study of Balsamic Bactrim
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02902640
- Locations
- 🇵🇪
Clinica San Borja; Instituto de Enfermedades Respiratorias EFEH, Lima, Peru
🇵🇪Clinica de Especialidades Medicas, Lima, Peru
🇵🇪Centro de Investigaciones Medicas/Hospital Maria Auxiliadora, San Juan de Miraflores, Peru
A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 339
- Registration Number
- NCT02901431
- Locations
- 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸University Hospitals, Cleveland, Ohio, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 243
- Registration Number
- NCT02896855
- Locations
- 🇨🇳
the First Hospital of Jilin University, Changchun, China
🇨🇳Changzhou First People's Hospital, Changzhou, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai City, China
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02892318
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸City of Hope, Duarte, California, United States